This is a medical question that neither the report nor this FAQ will answer. The appropriate person to answer this question is a physician who knows your medical history, current health status, existing medications, and individual risk factors.
What the report can honestly say is that for many adults, especially those who are obese or significantly overweight, the case for discussing GLP-1 drugs with a doctor is now strong enough that many major medical institutions and clinical guidelines support it. If you are struggling with obesity, type 2 diabetes, cardiovascular risk, or metabolic syndrome, you are likely already in the group for whom these drugs are now considered standard of care in many countries.
For adults who are not obese but are interested in health optimization such as better body composition, metabolic health, long-term disease prevention, the landscape is evolving. Low-dose GLP-1 use for maintenance and optimization is increasingly being explored and discussed clinically, but it is not yet established as standard practice the way high-dose obesity treatment is.
For the muscle-gain drugs (myostatin/activin blockers), the answer for most people today is not yet. These drugs are only now entering the market (apitegromab is expected in mid-late 2026) and their long-term safety profile for healthy optimization use has not been fully characterized. For people with specific medical conditions such as spinal muscular atrophy, cancer-related muscle wasting, or sarcopenia, these drugs may soon be appropriate under clinical supervision.
What the report does argue, more broadly, is that "medications you only take when something is wrong" will increasingly give way to the framing of HOTs as "tools you use to maintain your health," in the same way that most adults now routinely use vitamins, supplements, or other wellness interventions without requiring a formal diagnosis. We also discuss how, once that happens, these drugs will completely transform multiple industries across the global economy. At an individual level, if the potential of these medications excite you, the right starting point is an honest conversation with a qualified physician.
Witness the transformation
We are entering a new era of healthcare based on a categorically different kind of medicine whose purpose is not just to save us from illness, but to help us be the best version of ourselves.
The next generation of HOTs will trigger a multi-trillion-dollar global disruption, affecting dozens of industries across multiple sectors, driving a radical global improvement in health and wellness encompassing at least 1 billion people worldwide before 2040.
Optimizing well with advanced HOTs will soon become as important as eating well with nutritious foods. Nations, industries, and individuals that recognize this early and act decisively will be best positioned to capture the extraordinary benefits of this transformation.
Learn more about the HOT disruption and its implications for health, society, and the economy.
Disclaimer
The information provided in this FAQ is for general informational and educational purposes only and is not intended to constitute medical advice, diagnosis, or treatment. This content does not establish a doctor-patient relationship. The content regarding GLP-1 receptor agonists (or any other medical treatments) should not be used as a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment options. Never disregard professional medical advice or delay in seeking it because of something you have read here. The authors and publishers of this FAQ and related report make no representation or warranty, express or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any information presented. Reliance on any information provided here is solely at your own risk.